A late-stage trial showed that patients with acute hepatic porphyria saw therapeutic effects from treatment with givosiran after 12 months, and the drug maintained safety and efficacy during that time period. The number of patients who did not experience attacks rose from 50% in the first six months to 61.7% in the next six months.
Givosiran provides long-term benefits in AHP, study finds
Sign up for ACG SmartBrief
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.